| Outcome Measures: |
Primary: Area under the serum insulin concentration curve within 24 hours (INS-AUC0-24) after dosing on Day 6, 24-hours (D6 to D7) | Secondary: Maximum insulin concentration (INS-Cmax), 24-hours (D6 to D7)|Time to INS-Cmax (INS-tmax), 24-hours (D6 to D7)|Time to reach 50% of INS-AUC0-24 (T50%-INS-AUC0-24), 24-hours (D6 to D7)|Area under the body-weight-standardized Glucose Infusion Rate (GIR) within 24 hours (GIR-AUC0-24h) after dosing on Day 6 during the clamp, 24-hours (D6 to D7)|Maximum smoothed body weight standardized glucose infusion rate (GIRmax), 24-hours (D6 to D7)|Time to GIRmax (GIR-Tmax), 24-hours (D6 to D7)|Time to reach at least 50% of GIR-AUC0-24 (T50%-GIR-AUC0-24), 24-hours (D6 to D7)|Duration of blood glucose control (time to elevation of smoothed blood glucose profile above clamp level and to elevation above different prespecified blood glucose levels), 24-hours (D6 to D7)|Safety as measured by adverse events/serious adverse events, ohypoglycemia events, physical examinations, clinical laboratory, electrocardiograms, vital signs, injection site reactions and anti-insulin antibodies., up to 9 weeks
|
